Erin Willert
Profile
Erin Willert worked as an Executive Vice President-Research & Development and Senior Vice President-Research & Development at Molecular Templates, Inc. before earning a doctorate degree from The University of Texas Southwestern Medical Center.
Former positions of Erin Willert
| Companies | Position | End |
|---|---|---|
| MOLECULAR TEMPLATES, INC. | Chief Tech/Sci/R&D Officer | - |
Molecular Templates, Inc. /Old/
 Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Chief Tech/Sci/R&D Officer | - |
Training of Erin Willert
| The University of Texas Southwestern Medical Center | Doctorate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| MOLECULAR TEMPLATES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |
- Stock Market
- Insiders
- Erin Willert
